Wellington Management Group LLP Increases Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR

Wellington Management Group LLP boosted its position in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 1.6% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 7,379,433 shares of the company’s stock after buying an additional 119,146 shares during the period. Wellington Management Group LLP owned approximately 10.60% of Structure Therapeutics worth $396,054,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. CWM LLC lifted its stake in Structure Therapeutics by 35.2% during the 4th quarter. CWM LLC now owns 480 shares of the company’s stock valued at $33,000 after acquiring an additional 125 shares during the period. HighTower Advisors LLC raised its holdings in shares of Structure Therapeutics by 3.6% during the fourth quarter. HighTower Advisors LLC now owns 9,320 shares of the company’s stock worth $648,000 after purchasing an additional 320 shares during the last quarter. State of Wyoming lifted its position in Structure Therapeutics by 29.7% during the fourth quarter. State of Wyoming now owns 1,761 shares of the company’s stock valued at $122,000 after purchasing an additional 403 shares during the period. Assetmark Inc. lifted its position in Structure Therapeutics by 21.4% during the first quarter. Assetmark Inc. now owns 2,544 shares of the company’s stock valued at $123,000 after purchasing an additional 449 shares during the period. Finally, TrueMark Investments LLC boosted its holdings in Structure Therapeutics by 1.4% in the first quarter. TrueMark Investments LLC now owns 34,377 shares of the company’s stock valued at $1,657,000 after purchasing an additional 484 shares during the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on GPCR. Canaccord Genuity Group set a $111.00 price target on Structure Therapeutics in a research report on Friday, August 7th. Citizens Jmp lowered their target price on Structure Therapeutics from $113.00 to $110.00 and set a “market outperform” rating on the stock in a research note on Friday, August 7th. Citigroup reaffirmed a “market outperform” rating on shares of Structure Therapeutics in a report on Friday, August 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Friday, July 17th. Finally, Wall Street Zen raised Structure Therapeutics from a “strong sell” rating to a “sell” rating in a report on Monday, August 17th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $110.91.

Structure Therapeutics Stock Down 3.8%

NASDAQ:GPCR opened at $47.37 on Friday. Structure Therapeutics Inc. Sponsored ADR has a 52 week low of $18.26 and a 52 week high of $94.90. The stock’s 50-day moving average price is $50.80 and its 200-day moving average price is $50.50. The stock has a market capitalization of $3.30 billion, a PE ratio of -47.37 and a beta of -1.43.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). Sell-side analysts expect that Structure Therapeutics Inc. Sponsored ADR will post -1.84 earnings per share for the current fiscal year.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.